Nektar Therapeutics : Corporate Presentation September 2021

Nektar Therapeutics Corporate Presentation

September 2021

This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data.Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings with the SEC including the Form 10-Q filed on August 6, 2021.Nektar undertakes no obligation to update forward-looking statements as a result of new information or otherwise.

2

Nektar is Developing Innovative Medicines for Patients with Cancer and Autoimmune Diseases

		Program	Indication	Study	Preclinical		Phase 1	Phase 2	Phase 3
			Metastatic Melanoma	BEMPEG + OPDIVO® vs. OPDIVO®				Registrational Study
			Renal Cell Carcinoma	BEMPEG + OPDIVO® vs. TKI				Registrational Study
			Muscle-invasive Bladder Cancer	BEMPEG + OPDIVO® vs. OPDIVO®				Registrational Study
		Bempegaldesleukin	Adjuvant Melanoma	BEMPEG + OPDIVO® vs. OPDIVO®				Registrational Study
		(BEMPEG)	Bladder Cancer	BEMPEG + OPDIVO®			AA Registrational Study
		(NKTR-214)	Head & Neck SCC	BEMPEG + KEYTRUDA®				Phase 2/3
	Immuno-		Renal Cell Carcinoma	BEMPEG + OPDIVO® + TKI			Phase 1/2
		1L NSCLC	BEMPEG + KEYTRUDA®			Phase 1/2
	oncology
	Head & Neck SCC	BEMPEG + VB10.NEO	Phase 1/2a
		NKTR-262	Multiple Solid Tumors	NKTR-262 + BEMPEG			Phase 1/2
			R/R NHL or Multiple Myeloma	NKTR-255 + RITUXAN® or DARZALEX FASPRO®			Phase 1/2
			Head & Neck and Colorectal	NKTR-255 + ERBITUX®			Phase 1/2
		NKTR-255	ALL & DLBCL	NKTR-255 + CD19/22 CAR T-cell		Phase 1
			DLBCL	NKTR-255 + Liso-cel		Phase 1
			Systemic Lupus Erythematosus	LY3471851 / NKTR-358				Phase 2
	Immunology		Ulcerative Colitis	LY3471851 / NKTR-358				Phase 2
	LY3471851 / NKTR-358	Psoriasis	LY3471851 / NKTR-358			Phase 1b
			Atopic Dermatitis	LY3471851 / NKTR-358			Phase 1b
	Virology	BEMPEG	COVID-19	BEMPEG	Phase 1
	NKTR-255	Virology	NKTR-255

Opdivo is a registered trademark of Bristol-Myers Squibb Company; Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.; Rituxan is a registered trademark of Biogen; Darzalex Faspro is a registered trademark of Janssen Biotech, Inc.; Erbitux is a registered trademark of ImClone LLC., a subsidiary of Eli Lilly & Co.; AA: Accelerated Approval

|

3

Nektar is Leading the Development of Cytokine-Based Therapies

IL-2

IL-15

			IL-2
beta	(CD25)	gamma	Immune
Activation
	alpha
(CD122)		(CD132)

Dimeric IL-2R

IL-2

IL-2 Receptor (IL-2R)

subunits Immune

Regulation

Trimeric IL-2R

IL-15Rα

Immune

Stimulation

IL-15

BEMPEG (CD122-BiasedIL-2 Pathway Agonist)

Prime, Proliferate, Activate & Increase Tumor-Infiltrating Lymphocytes (TILs), Increase PD-1 expression

NKTR-358(IL-2 Pathway Conjugate)

A conjugated IL-2 agonist biased for T regulatory cell expansion

NKTR-255(IL-15 Receptor Agonist)

Stimulate and expand NK Cells & Promote survival and expansion of memory CD8+ T cells

4

Capturing the Potential of the IL-2 Pathway in Immuno-Oncology:

Bempegaldesleukin Designed to Stimulate T-Cell Proliferation

Bempegaldesleukin

IL-2 Receptor	IL-2 signaling	Cell activation & proliferation	Immune system stimulation
	alpha		to IL-2Rbeta-gamma
beta	(CD25)	gamma	IL-2
(CD122)	(CD132)
				Cytotoxic T cell
IL-2 Receptor	Dimeric IL-2R
	Subunits
				Natural Killer (NK) Cell	Tumor cell

• Preferentially signals IL-2Rbeta-gamma complex to stimulate cytotoxic T cells
• Retains some transient binding to the alpha receptor to enhance priming in lymph nodes
• Prodrug design and receptor bias eliminate over-activation of IL-2 pathway
• Achieves antibody-like dosing schedule in outpatient setting

5